Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3865 Prospective observational study on third-line treatments in neuroendocrine carcinoma – Data from the phase II SENECA trial

Introduction: Neuroendocrine Carcinoma (NEC) are very rare and characterized by a poor prognosis. Therapeutic opportunities for metastatic disease beyond the first line are very limited.

Conference:

Presenting Author: Liverani C

Authors: Bongiovanni A, Liverani C, Morbini S, Pusceddu S, Gelso F,

Keywords: neuroendocrine carcinoma, FOLFIRI, CAPTEM, third line, chemotherapy,

#3776 Long-term effects of peptide receptor radionuclide therapy (PRRT) used as first-line treatment of GEP-NET – A single centre experience

Introduction: Peptide receptor radionuclide therapy (PRRT) is a well-recognized treatment option for inoperable/metastatic somatostatin receptor-positive neuroendocrine tumors (NET) currently according to guidelines used as second or third line of treatment.

Conference:

Presenting Author:

Authors: Opalinska M, Sowa-Staszczak A, Kurzyńska A, Morawiec-Sławek K, Olearska H,

Keywords: PRRT, first-line treatment, outcome, GEP-NET, NET,

#3420 Etoposide-based rechallenge and second/third line treatments in patients with metastatic neuroendocrine carcinoma: Results from the multicenter RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network

Introduction: Neuroendocrine carcinomas (NEC) are aggressive malignant diseases. Etoposide-based rechallenge (EBR) and the prognostic role of Rb status in second-line (SL) have not been studied.

Conference:

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Walter T, Hescot S, Hautefeuille V,

Keywords: Neuroendocrine carcinoma, Rb, rechallenge,